Antidepressant Long-Term Efficacy Pre-Approval Would Delay New Therapies
Executive Summary
FDA's Psychopharmacologic Drugs Advisory Committee on Oct. 25 agreed with industry's key argument that the proposed requirement to complete long-term efficacy studies at the time of approval for major depressive disorder drugs would delay the entry of new therapies to market
You may also be interested in...
FDA Stance On Antidepressant Warnings Unchanged By NIMH Suicide Findings
A National Institute of Mental Health-funded study showing no increased risk of suicide with newer antidepressants does not change FDA's stance on the need for warnings about suicidality for the drug class